PDF(Pubmed)
Abstract：
This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.
摘要：
本系统评价评估了呼吸道合胞病毒（RSV）在拉丁美洲和加勒比地区（LAC）对医疗保健资源利用和相关成本的经济影响。我们检索了2012年1月至2022年11月的在线数据库，以确定符合条件的出版物。我们确定了12种报告直接成本的出版物，间接成本，以及与RSV及其并发症相关的资源。报告的主要直接医疗资源是医疗服务，诊断测试和程序，和停留时间（LOS）。每位患者的直接总成本从563美元到19,076美元不等。直接成本是,平均而言,比间接成本高98%。巴西报告每位患者的总费用高于哥伦比亚，萨尔瓦多,墨西哥,Panamá,波多黎各,而对于每位患者的间接成本，萨尔瓦多和巴拿马的费用比巴西高，哥伦比亚,和墨西哥。普通病房因RSV导致的平均LOS为6.9天（范围为4至20天），重症监护病房的平均LOS为9.1天（范围为4至16天）。在拉丁美洲和加勒比区域的许多国家，RSV对卫生系统构成了相当大的经济负担，但在该地区发现了显著的证据差距。更严格的卫生经济研究对于更好地了解这一负担并通过明智的决策过程促进有效的医疗保健至关重要。针对RSV的疫苗接种在减轻这种负担方面起着关键作用，应成为公共卫生战略的优先事项。
